151 related articles for article (PubMed ID: 2645036)
21. [The prospect for cisplatin analogs from the experimental standpoint].
Tashiro T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1358-65. PubMed ID: 2543305
[TBL] [Abstract][Full Text] [Related]
22. [Antitumor effect of carboplatin and iproplatin on human urinary bladder and prostatic cancers grown in nude mice].
Hasegawa J; Kawamura N; Yamada S; Tsuboi N; Akimoto M
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3279-83. PubMed ID: 3318705
[TBL] [Abstract][Full Text] [Related]
23. A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.
Foster BJ; Harding BJ; Wolpert-DeFilippes MK; Rubinstein LY; Clagett-Carr K; Leyland-Jones B
Cancer Chemother Pharmacol; 1990; 25(6):395-404. PubMed ID: 2178792
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of cis-platin and carboplatin in the chemotherapy of squamous cell carcinoma grown as multicellular spheroids.
Schwachöfer JH; Crooijmans RP; Hoogenhout J; Kal HB; Theeuwes AG
Anticancer Res; 1990; 10(3):805-11. PubMed ID: 2195988
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of the antitumor activity of newly developed platinum analogs in lung cancer using the colony assay].
Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Yamashita H; Kozuka A; Moritaka T; Uji H; Kiura K; Mima Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):427-30. PubMed ID: 2539056
[No Abstract] [Full Text] [Related]
26. Comparative effect of cisplatin, spiroplatin, carboplatin and iproplatin in a human tumor clonogenic assay.
Schroyens W; Dodion P; Rozencweig M
J Cancer Res Clin Oncol; 1990; 116(4):392-6. PubMed ID: 2202731
[TBL] [Abstract][Full Text] [Related]
27. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma.
Riccardi A; Meco D; Ferlini C; Servidei T; Carelli G; Segni G; Manzotti C; Riccardi R
Cancer Chemother Pharmacol; 2001 Jun; 47(6):498-504. PubMed ID: 11459202
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
[TBL] [Abstract][Full Text] [Related]
30. Preclinical antitumor activity of orally administered platinum (IV) complexes.
Rose WC; Crosswell AR; Schurig JE; Casazza AM
Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
[TBL] [Abstract][Full Text] [Related]
31. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Boven E; van der Vijgh WJ; Nauta MM; Schlüper HM; Pinedo HM
Cancer Res; 1985 Jan; 45(1):86-90. PubMed ID: 4038381
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
34. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).
Skillen AW; Buamah PK; Cantwell BM; Cornell C; Hodson AW; Harris AL
Cancer Chemother Pharmacol; 1988; 22(3):228-34. PubMed ID: 3044631
[TBL] [Abstract][Full Text] [Related]
35. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
36. Synergistic interaction between platinum-based antitumor agents and demethylcantharidin.
To KK; Ho YP; Au-Yeung SC
Cancer Lett; 2005 Jun; 223(2):227-37. PubMed ID: 15896457
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
38. In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin.
Dodion P; Sanders C; Georges P; Kenis Y
Cancer Chemother Pharmacol; 1988; 22(1):80-2. PubMed ID: 3293841
[TBL] [Abstract][Full Text] [Related]
39. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
40. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
Hills CA; Kelland LR; Abel G; Siracky J; Wilson AP; Harrap KR
Br J Cancer; 1989 Apr; 59(4):527-34. PubMed ID: 2653399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
